← Back to Search

GLP-1 Receptor Agonist

GLP-1 Agonists for Osteoporosis

Phase 2
Recruiting
Led By Vishnu V Garla, MD
Research Sponsored by University of Mississippi Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Postmenopausal female
Age >55 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months after index date
Awards & highlights

Study Summary

This trial will help show if GLP-1 receptor agonists help improve bone strength in postmenopausal women with T2DM.

Eligible Conditions
  • Osteoporosis
  • Type 2 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
A woman who has gone through menopause.
Select...
You are older than 55 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months after index date
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months after index date for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Trabecular bone score
Secondary outcome measures
Inflammatory markers and Bone resorption markers
Sclerostin and Bone formation markers
Visceral fat mass

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GLP-1 cohortExperimental Treatment1 Intervention
Participants on GLP-1 receptor agonists
Group II: Non GLP-1 cohortActive Control1 Intervention
Participants not on GLP-1 receptor agonists
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GLP-1 receptor agonist
2020
Completed Phase 3
~11540

Find a Location

Who is running the clinical trial?

University of Mississippi Medical CenterLead Sponsor
171 Previous Clinical Trials
194,967 Total Patients Enrolled
1 Trials studying Osteoporosis
197 Patients Enrolled for Osteoporosis
Vishnu V Garla, MDPrincipal InvestigatorUniversity of Mississippi Medical Center

Media Library

GLP-1 receptor agonist (GLP-1 Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT04964388 — Phase 2
Osteoporosis Research Study Groups: GLP-1 cohort, Non GLP-1 cohort
Osteoporosis Clinical Trial 2023: GLP-1 receptor agonist Highlights & Side Effects. Trial Name: NCT04964388 — Phase 2
GLP-1 receptor agonist (GLP-1 Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04964388 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree are GLP-1 receptor agonists causing adverse effects in patients?

"Our team has assigned a score of 2 to GLP-1 receptor agonist in terms of safety, since the medication is currently being tested during Phase 2. This indicates that while there is evidence supporting its security profile, efficacy must still be established."

Answered by AI

What is the current recruitment rate of participants for this experiment?

"Affirmative. According to clinicaltrials.gov, this trial is currently on the hunt for participants and was originally posted on November 9th 2021. The most recent update occured on August 19th 2022 and 48 patients are being recruited from just one location."

Answered by AI

Is there currently an opportunity to enroll in this medical research?

"Affirmative, this clinical trial is currently searching for participants. It was first advertised on November 9th 2021 and the data was most recently updated on August 19th 2022."

Answered by AI
~14 spots leftby Mar 2025